Xbrane Biopharma (Sweden) Probability of Future Stock Price Finishing Over 0.17
| XBRANE Stock | SEK 0.19 0.01 5.56% |
Xbrane |
Xbrane Biopharma Target Price Odds to finish over 0.17
The tendency of Xbrane Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above kr 0.17 in 90 days |
| 0.19 | 90 days | 0.17 | about 63.86 |
Based on a normal probability distribution, the odds of Xbrane Biopharma to stay above kr 0.17 in 90 days from now is about 63.86 (This Xbrane Biopharma AB probability density function shows the probability of Xbrane Stock to fall within a particular range of prices over 90 days) . Probability of Xbrane Biopharma price to stay between kr 0.17 and its current price of kr0.19 at the end of the 90-day period is about 27.71 .
Assuming the 90 days trading horizon Xbrane Biopharma AB has a beta of -0.7. This entails as returns on the benchmark increase, returns on holding Xbrane Biopharma are expected to decrease at a much lower rate. During a bear market, however, Xbrane Biopharma AB is likely to outperform the market. Additionally Xbrane Biopharma AB has an alpha of 0.6381, implying that it can generate a 0.64 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Xbrane Biopharma Price Density |
| Price |
Predictive Modules for Xbrane Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Xbrane Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Xbrane Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Xbrane Biopharma is not an exception. The market had few large corrections towards the Xbrane Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Xbrane Biopharma AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Xbrane Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.64 | |
β | Beta against Dow Jones | -0.7 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | 0.06 |
Xbrane Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Xbrane Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Xbrane Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Xbrane Biopharma is way too risky over 90 days horizon | |
| Xbrane Biopharma has some characteristics of a very speculative penny stock | |
| Xbrane Biopharma appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 11.53 M. Net Loss for the year was (188.38 M) with loss before overhead, payroll, taxes, and interest of (18.27 M). | |
| Xbrane Biopharma AB has accumulated about 44.32 M in cash with (219.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of the company outstanding shares are owned by insiders |
Xbrane Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Xbrane Stock often depends not only on the future outlook of the current and potential Xbrane Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Xbrane Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 23.6 M | |
| Cash And Short Term Investments | 295.2 M |
Xbrane Biopharma Technical Analysis
Xbrane Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Xbrane Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Xbrane Biopharma AB. In general, you should focus on analyzing Xbrane Stock price patterns and their correlations with different microeconomic environments and drivers.
Xbrane Biopharma Predictive Forecast Models
Xbrane Biopharma's time-series forecasting models is one of many Xbrane Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Xbrane Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Xbrane Biopharma
Checking the ongoing alerts about Xbrane Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Xbrane Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Xbrane Biopharma is way too risky over 90 days horizon | |
| Xbrane Biopharma has some characteristics of a very speculative penny stock | |
| Xbrane Biopharma appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 11.53 M. Net Loss for the year was (188.38 M) with loss before overhead, payroll, taxes, and interest of (18.27 M). | |
| Xbrane Biopharma AB has accumulated about 44.32 M in cash with (219.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of the company outstanding shares are owned by insiders |
Other Information on Investing in Xbrane Stock
Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.